Fermentalg Reports 36% Revenue Growth in Q1 2025

Libourne-based Fermentalg has reported a 36% increase in revenue for the first quarter of 2025, amounting to €3.6 million, up from €2.7 million in the same period of the previous year. The robust growth is attributed to the company's strategy of diversifying into new market segments, specifically targeting the pet food, infant formula, and aquaculture sectors with its European-produced algal DHA product, DHA Origins™.

With ongoing geopolitical challenges affecting fish-derived omega-3 availability, Fermentalg's sustainable alternative has gained traction. Strategic efforts are bolstered by a partnership with Huvepharma, enhancing industrial performance and market entry competitiveness.

Fermentalg reaffirms its ambition to reach at least €25 million in annual revenue by 2026, a goal supported through increased sales, strategic partnerships, and continuous innovation. The company anticipates further revenue growth in 2025 compared to prior years.